Search Results for: Pharma: Other News to Note
-
Optimer Hoping for 'Impactful' Launch with Dificid in CDAD
Assistant Managing Editor After a three-day weekend to digest the news of Optimer Pharmaceuticals Inc.'s approval for macrolide antibiotic Dificid (fidaxomicin), investors jumped on the San Diego-based firm's stock (NASDAQ:OPTR) Tuesday, which, trading at seven times its average volume, gained $1.53, or 11.8 percent, to close at $14.51...Theravance Inc.'s Vibativ (telavancin), for instance, has seen sluggish sales since its approval in 2009 in complicated skin and skin structure infections -
Other News To Note
In other news, Astellas Pharma Europe Ltd., of Staines, UK, and Theravance Inc., of South San Francisco, announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency recommended the granting of marketing authorization for Vibativ (telavancin hydrochloride) for the treatment of adults with nosocomial pneumonia including ventilator-associated pneumonia, known or suspected to be caused by methicillin-resistant Staphylococcus aureus...Pharma Two B, of Rehovot -
Other News To Note
Astellas Pharma Inc., of Tokyo, completed its purchase of Maxygen Inc.'s 83.3 percent equity interest in Perseid Therapeutics LLC for $76 million...Tekmira Pharmaceuticals Corp., of Vancouver, British Columbia, expanded its collaboration with Bristol-Myers Squibb Co. (BMS), of New York, to include the evaluation of Tekmira's newly developed lipid nanoparticle formulations designed for delivery to tumors and other tissues outside the liver -
Other News To Note
Nuvo also agreed to issue a $14.9 million promissory note to ZARS shareholders upon the achievement of a milestone related to ZARS' Pliaglis, a topical local anesthetic cream, and Nuvo may issue up to an additional $8 million of promissory notes upon the occurrence of future events -
Other News To Note
Astellas Pharma Inc., of Tokyo, and Medivation Inc., of San Francisco, treated their first patient in a Phase II trial of MDV3100, an oral androgen receptor agonist, for prostate cancer...In other news, Sanofi-Aventis said that the company terminated its potential $375 million, July 2010 license agreement with Metabolex Inc., of Hayward, Calif., for diabetes drug SAR260093/MBX-2982, a GPR119 receptor agonist -
Other News To Note
Acceleron Pharma Inc., of Cambridge, Mass., presented preclinical data showing RAP-661 increased bone mineral density, increased osteoblast activity and decreased osteoclast activity in a mouse model of bone loss -
Other Financings Of Public Biotechnology Companies: April 2011
Pharma Inc. (Redwood City, Calif.) Private placement of convertible notes N/A $4.5 A.P. Pharma is raising $4.5M through certain investors, including Tang Capital Partners (4/26) ARCA Biopharma Inc. (Broomfield, Colo.) Registered direct offering 1.68S $3 ARCA is selling $3M of its common stock and warrants to institutional investors, issuing 1.68M shares and warrants to purchase about 1.18M shares (4/19) Benitec Ltd. (Melbourne, Australia) Rights issue 400.6S A$8 ($8.4 -
Other News To Note
Compass plans to use the technology to develop a heat-stable hepatitis B vaccine through C-Pharma, its wholly owned subsidiary...Durata said in December 2010 it acquired from Japan-based RaQualia Pharma Inc -
Other News To Note
The MARQUEE study will test tivantinib plus Tarceva (erlotinib, Astellas Pharma Inc. and Roche AG) vs. Tarceva plus placebo in patients who have received prior treatment...Zealand Pharma A/S, of Copenhagen, Denmark, and Sanofi-Aventis S/A, of Paris, reported top-line results from the GetGoal-S Phase III trial of lixisenatide in Type II diabetes showing the drug achieved its primary efficacy endpoint of significant HbA1c reduction, improving glycemic control from baseline as compared to placebo, and -
Other News To Note
The business refocus would also allow its Compass's hepatitis C project to continue sheltered with in C-Pharma Inc., while parent company Compass pursues generics, biosimilars and bio-betters...Valeant Pharmaceuticals International Inc., of Mississauga, Ontario, filed a presentation to stockholders of Cephalon Inc., of Frazer, Pa., with the SEC regarding its proposed removal of Cephalon's board of directors and election of seven other nominees in their place -
FDA Reverses, Approves XenoPort's Horizant for RLS
Approval triggers a $7 million milestone payment from XenoPort's Asian partner Astellas Pharma Inc., of Tokyo, and the product's launch triggers a $30 million milestone payment from development partner GlaxoSmithKline plc, of London, bringing up-front payments to $245 million...Once absorbed, Horizant is converted into gabapentin, which binds to a specific type of calcium channel, but does not exhibit affinity for other common receptors...We expect the sales reps selling Horizant to focus on the lack -
Other News To Note
ERYtech Pharma Inc., of Lyon, France, completed enrollment and safety follow-up in a Phase II trial of GRASPA (encapsulated L-asparaginase in red blood cells) in first-line acute lymphoblastic leukemia in patients older than 55 -
Other News To Note
MediGene AG, of Martinsried, Germany, completed the transfer of exclusive European rights to Eligard (leuprolide acetate) for the treatment of hormone-dependent prostate cancer to Astellas Pharma Europe Ltd., of London, part of Astellas Pharma Inc -
Other News To Note
As part of the agreement, Corden Pharma contracted with Genzyme to provide materials needed for the production of eliglustat tartrate, an investigational treatment for Gaucher disease Type 1 that's in Phase III trials, and for the manufacture of other treatments...MediGene AG, of Martinsried, Germany, completed the transfer of exclusive European rights to Eligard (leuprolide acetate) for the treatment of hormone-dependent prostate cancer to Astellas Pharma Europe Ltd., of London, part of Astellas -
Other News To Note
AspenBio Pharma Inc., of Castle Rock, Colo., has been given an additional 180-day extension to remain listed on the Nasdaq Capital Market and regain compliance with the exchange's $1 minimum bid price rule -
Other News To Note
Cell Signaling Technology Inc., of Danvers, Mass., announced a joint commercialization partnership with Astellas Pharma Inc., of Tokyo, focused on the delivery of personalized cancer therapeutics and diagnostics...According to findings published recently in the Journal of Clinical Oncology, the vaccine elicited immune responses in 81 percent of evaluable patients -
Other News To Note
A.P. Pharma Inc., of Redwood City, Calif., said it arranged Type B meetings with the FDA later this quarter to address the complete response letter for APF530 for the prevention of chemotherapy-induced nausea and vomiting -
Other News To Note
Astellas Pharma Inc., of Tokyo, engaged Citigroup Global Markets Inc...In other news, LifeCycle reported positive top-line results from a Phase II trial of 58 patients comparing LCP-Tacro tablets administered once daily vs. Prograf (tacrolimus, Astellas Pharma US Inc.) capsules administered twice daily in de novo liver transplant patients for one year -
Seattle Genetics Inks $200M Licensing Deal with Pfizer
In exchange, Genentech gained access to a number of targets. (See BioWorld Today, Aug. 4, 2010.) And in December 2009, Seagen closed its $402 million deal with GlaxoSmithKline and a deal with Astellas Pharma Inc., an affiliate of Agensys Inc., for $12 million up front with $350 million in milestones -
Other News To Note
Astellas Pharma Inc., of Tokyo, engaged Citigroup Global Markets Inc...Resolvyx Pharmaceuticals Inc., of Cambridge, Mass., and Celtic Therapeutics Holdings LP, of New York, entered a final agreement under which Celtic has acquired and licensed worldwide rights related to RX-10045, a late-stage program in dry eye syndrome and other ophthalmic indications
Category
Current Filters
- xPharma Inc
Related Keywords
Categories
- x BioWorld Today (853)
- x BioWorld International (109)
- x BioWorld Insight (23)
- x Bio Perspectives (6)
- x State of the Industry Report (3)
- x BioWorld Snapshots (1)